BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Aclaris Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Aclaris Therapeutics's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07935590-1297@assetmemo.bio
DTSTAMP:20261121T005933Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Modzatinib: Phase 2 readout est. (NCT07935590)
DESCRIPTION:Modzatinib\, phase 2.\nStudy: Study of Modzatinib (ATI-2138) in
  Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequate
 ly Controlled With Topical Therapies\nEstimated primary completion: March 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/modzatinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07935590
URL:https://assetmemo.bio/drug/modzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
